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Background: Cardiopulmonary bypass (CPB) is an immuno-reactive state where neutrophils are activated and
accumulate in different tissues. Edema and tissue necrosis are the most common sequelae observed, predominantly
in the lungs, kidneys, and heart, heralding significant risk for postoperative complications. No method exists to
noninvasively assess in vivo neutrophil activity. The objective of this study was to determine if neutrophil recruitment
to the oral cavity would correlate with specific biomarkers after coronary bypass surgery (CPB).
Methods: We conducted a single site prospective observational study including non-consecutive adult patients
undergoing elective, on-pump CPB. Blood and either oral cavity rinses or swabs were collected pre- and post-CPB.
Absolute neutrophil counts from oral samples and serum biomarkers were measured. The association between neutrophil
recruitment to the oral cavity, biomarkers and outcomes after CPB were analyzed.
Results: CPB was associated with statistically significant increases in oral and blood neutrophil counts, as well as an
increase in certain biomarkers over preoperative baseline. Peripheral blood neutrophil count were increased at all time
points however statistically significant differences in median oral neutrophil counts were observed only at the time point
immediately postoperative, and in what seems to be two unique patient populations (p < 0.001; group 1, median:
1.6×105, Interquartile range [IQR], 1.1×105 - 4.8×105, and group 2, median: 1.9×106, IQR, 8.7×105 - 4.0×106).
Conclusions: CPB is associated with a transient increase in oral neutrophils that may correlate with the systemic
inflammatory response; oral neutrophils may have the ability to discriminate and identify unique patient populations
based on their tissue migration.
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The innate immune system provides the host with an im-
mediate but non-specific response to infection. Although
inflammation is an essential response, its onset and pro-
gression may become “dysregulated”, resulting in a
massive and uncontrolled release of proinflammatory me-
diators that may lead to widespread tissue injury [1]. The
systemic inflammatory response system (SIRS) is a com-
plex clinical syndrome involving complement activation,* Correspondence: elizabeth.wilcox@mail.utoronto.ca
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Neutrophils play a pivotal role in defense as they contain
and destroy causative organisms after breaching host ana-
tomical barriers, such as the skin and mucosa. Neutrophil-
mediated organ dysfunction has been implicated as playing
a causative role in the high rates of morbidity and mortality
in SIRS patients [2].
Coronary artery bypass grafting (CABG) is a well-
established treatment for ischemic heart disease. It is
traditionally performed using cardiopulmonary bypass
(CPB), termed “on-pump CABG”. CPB is an immuno-
reactive state, where polymorphonuclear (PMN) cells are
activated through contact with the synthetic surfaces ofLtd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Wilcox et al. Journal of Inflammation 2014, 11:32 Page 2 of 11
http://www.journal-inflammation.com/content/11/1/32the bypass circuit, mechanical shear stress and hemodilu-
tion, [3-6] and as a result accumulate in different tissues.
Nonrandomized studies have shown a marked difference
in complement activation (C3a, C5a) between on-pump
and off-pump CPB patients [7]. Similar such studies have
shown a significant and persistent increase in lymphocytes
and neutrophils postoperatively in on-pump CPB patients
when compared to off-pump CPB patients [8]. This wide-
spread PMN activation generates an abundance of oxygen
and hydroxyl free radicals that can exacerbate the release
of granular constituents such as elastase and myeloperoxi-
dase into surrounding tissues. Edema and tissue necrosis
are the most common sequelae observed predominantly
in the lungs, kidneys and heart heralding significant risk
for postoperative complications [9,10]. Examination of
autopsy specimens from patients with multiple organ fail-
ure (MOF) revealed localization of neutrophils in both
renal blood vessel aggregates and large-scale infiltration of
the lung tissues [11]. In acute lung injury, the intensity of
neutrophil infiltrates correlates with impaired lung func-
tion and with high concentrations of neutrophil-derived
proteolytic enzymes in bronchoalveolar lavage [12].
Currently there is no rapid non-invasive method of
assessing in vivo neutrophil function as a surrogate of an
individual’s innate immune function. The standard routine
measure for assessing a patient’s innate immune status in-
volves monitoring circulating PMN levels. While this is an
informative clinical parameter as it relates to cell numbers,
it provides no information about cell functionality or the
efficiency with which these cells reach the site of infection
and eliminate microbial burden. The primary role of a
neutrophil is to eliminate microbes at sites distant from
the circulation. While monitoring neutrophil recruitment
to tissues following CPB may be beneficial in determining
those patients who are more susceptible to CPB-related
morbidity, tissue biopsy is invasive and impractical.
Research suggests that the oral cavity may provide an
early opportunity to non-invasively monitor the innate
immune system [13-15]. The oral cavity is optimal for
this as it contains an ever-present bacterial biofilm on
teeth, tongue and other shedding surfaces. This bacterial
presence is kept under control, in part, by the constant
influx of neutrophils that migrate into the mouth from
the periodontal tissues, which surround and support the
teeth [16]. The recruitment of neutrophils by the oral
biofilm may serve as a non-invasive measure of in vivo
systemic neutrophil activation and chemotaxis [13-15].
The primary aim of this study was to show that CPB in-
creases oral neutrophil counts, measured by oral rinses or
swabs. The secondary aims were to demonstrate that CPB
is associated with a change in oral neutrophil counts, in-
dependent of its effect on neutrophils in the peripheral
circulation, and that changes are seen in levels of both
pro- and anti-inflammatory biomarkers. Our hypothesiswas that changes in oral neutrophil counts would correlate
with specific biomarkers after CPB and possibly be associ-
ated with CPB-related morbidity. CPB induced changes in
oral neutrophils could also demonstrate proof of concept
for exploring oral neutrophil counts as marker for neutro-
phil activation in other inflammatory states seen in critical
care.
Methods
The Sunnybrook Health Sciences Centre Research Ethics
Board approved this protocol. Written consent was pro-
vided by study participants.
Study subjects
Adult patients (>18 years of age) undergoing elective, on-
pump cardiopulmonary bypass surgery were enrolled in
this study at Sunnybrook Health Sciences Centre following
attainment of informed consent. Exclusion criteria in-
cluded: existing oral disease (e.g. oral cancer, congenital or
acquired chronic mucocutaneous disease), ongoing infec-
tion (e.g. endocarditis), recent myocardial infarct (i.e. within
2 weeks), pregnancy, pre-existence of any autoimmune or
immune deficiency disease and/or patients who had been
treated with steroids or other immunosuppressive agents
within the previous 30 days.
Sample collection and frequency
Either a brief oral rinse or swab was performed to collect
neutrophils from the oral cavity. Oral rinses were not
performed while a patient was intubated and mechanic-
ally ventilated due to the risk of aspiration. For the oral
rinse sample, patients rinsed with 10 mLs of sterile nor-
mal saline (9%) for 30 seconds [14,17]. Samples for the
oral swab, were obtained from four-quadrant gingival
swabs [13]. Oral neutrophil samples were obtained from
patients pre-operatively (T0) and postoperatively upon
arrival to the CVICU (T1), at 12–18 hours (T2), and on
day 3 (T3). All samples were stored at 4°C prior to trans-
portation to the lab for analysis.
Assessment of oral PMN levels
The protocol used to collect and count oral PMNs was a
modification of previous work [18,19]. Each oral collec-
tion sample was collected in a sterile vial and stored at
4°C to preserve the cells prior to transportation to the
laboratory for processing. All samples were processed
within 24 hours of collection; the oral rinse sample
underwent centrifugation at 2500 RPM for 5 minutes at
21°C (Hettich Rotina 35R, Rare Scientific, Edmonton,
Canada). The cell pellet was re-suspended in 1 mL of
double distilled water. Twenty milligrams of 2,2′-azino-
bis(3-ethylbenzo-thiazoline-6-sulfonic acid) (ABTS; AO;
Sigma Chemical, Burlington, Canada) was dissolved in
3.6 mL of 1 MM phosphocitrate buffer to produce a 1X
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ide was added to 3.952 mL of double distilled water to
produce a hydrogen peroxide homogenous solution. For
each 1 mL concentrated oral rinse sample, 100 μL of the
ABTS solution followed by 100 μL of 30% hydrogen per-
oxide solution was added in order to observe the charac-
teristic blue-green colour change. After the colour
reaction was complete, 250 μL of the sample was added
to a 96 well plate in triplicate. The absorbance was mea-
sured at 420 nm for 10 cycles at 180 seconds per cycle
using an automated microplate reader software (FLUOs-
tar OPTIMA; BMG LABTECH GmbH, Offenburg,
Germany). The final absorbance value for a sample was
given as the average of the absorbance values of the cy-
cles and of the triplicate measurements. The average
standard deviation and coefficient of variation of the ab-
sorbance of the 10 cycles for all the collected samples
was 0.09 and 6.34% respectively indicating a very low
variation between the cycle absorbance readings. In
order to determine the PMN counts within a given oral
rinse sample based on the absorbance measure, a stand-
ard curve equation was used (y = 3305783.5X-1366). A
series of standard solutions were prepared in the lab as
described above, using neutrophils of known numbers/
concentrations. The absorbance was then measured at
420 nm for 10 cycles at 180 seconds per cycle using the
software (FLUOstar OPTIMA; BMG LABTECH GmbH,
Offenburg, Germany). The standard curve equation was
then obtained by plotting the absorbance of the standard
solutions versus the known concentrations, thus allow-
ing deduction of the PMN counts using the absorbance
value obtained for any one sample.Blood neutrophil counts
Daily routine circulating white blood cell differential
counts were used to compare with oral neutrophils. Values
approximating most closely to the time of oral neutrophil
collection were used. For patients that were still in hospital
at day 7, the differential neutrophil count was used for
comparative analysis.Biomarker analysis
All subjects received concurrent blood draws. Samples
were drawn in ethylenediaminetetraacetic acid and cit-
rate tubes, centrifuged at 1700 × 2 g at 4°C for 20 mins,
plasma was collected and frozen in cryogenic tubes
at −80°C within hours of collection. Plasma was assayed
for Interleukin (IL)-1β, IL-2, IL-6, IL-10, IL-12, IL-17,
IL-1RA, monocyte chemotactic protein (MCP)-1, soluble
intercellular adhesion molecule (sICAM), granulocyte/
macrophage colony-stimulating factor (GM-CSF) using
a Luminex mediator panel with Multiplexing immunoas-
says instrument (Luminex technology, Austin, USA). Allassays were performed in duplicate with the average
level used in the analysis.
Clinical parameters
Comprehensive clinical data was collected on the day of
admission and through out the duration of the study, in-
cluding: demographics, baseline characteristics (e.g. risk
factors for coronary artery disease, medications, etc.), de-
tails of the surgical procedure and postoperative course
(e.g. duration of mechanical ventilation, length of stay
(LOS), documented infections (respiratory, urinary and
catheter infections), and incidence of acute renal failure
or need for renal replacement therapy (RRT).
Statistical analysis
Continuous variables were summarized with means (stand-
ard deviation, SD) or medians and IQR and categorical var-
iables were summarized using frequencies and percentages.
The degree of association between oral neutrophil counts
(swab and rinse) was determined using Spearman’s correl-
ation [20]. Changes between preoperative and postoperative
neutrophil counts were compared using Wilcoxon signed-
rank test. To compare the changes in the oral swab be-
tween groups with low baseline oral neutrophils and high
baseline neutrophils we used Wilcoxon rank-sum test. As-
sociation between change in oral neutrophil counts and
measured cytokines in blood samples was compared using
Spearman rank correlation coefficient (all values were
transformed to a logarithmic scale for analysis). Linear re-
gression was used to determine the association of measured
covariates and change in pre- and postoperative oral neu-
trophil counts. Consideration for inclusion of a variable in
the multivariable model required a p-value <0.2 in the uni-
variable analysis. Differences were considered significant at
p-value ≤0.05. All analyses were performed without adjust-
ing for multiple-comparison using SAS 9.3 (SAS Institute
Inc., Cary, NC, USA).
Results
Population characteristics
There were 41 patients enrolled with a median age of
67 years (IQR, 60–72), years; 78% were male; 76% were
Caucasian; and there was a high co-morbid burden of
disease: diabetes mellitus (24%), hypertension (73%), and
renal disease (20%) (Table 1). CPB was indicated for 21
(51%) valve replacements and 20 (49%) vessel grafts: sin-
gle vessel (10%), double bypass (20%), triple bypass
(50%) and quadruple bypass (20%). The median length
of time spent on bypass was 132 mins (IQR, 113–148
mins) and with the aorta cross-clamped 107 mins (IQR,
93–122 mins). Acute Physiology and Chronic Health
Evaluation (APACHE) II and Multiple Organ Dysfunction
Score (MODS) scores were 22 (SD ±4) and 6.2 (SD ±2.2),
respectively on the day of admission (Table 1). Patients
Table 1 Baseline characteristics of patients in study
(n = 41)
Characteristic Mean (SD)
Age – yrs 67 (60–72)
Male sex – no. (%) 32 (78)
Co-morbidities
Diabetes Mellitus
(requiring OHGs or insulin) – no. (%)
10 (24)
Smoking status reported as active – no. (%) 5 (12)
Hypertension 30 (73)
Renal insufficiency 8 (20)
Medication use – no. (%)
Statin 22 (54)
NSAID 2 (5)
ACE Inhibitor 13 (32)
Details of Surgery
CPB time – mins* 132 (113–148)
Cross-clamp time – mins* 107 (93–122)
Temperature (low) – degrees Celsius* 32.2 (31.6–33.1)
Blood transfusion within 0–6 hrs of CPB initiation 10 (24)
Postoperative course
Delta creatinine (baseline – immediate
postoperative; μmol/L)*
3 (–2,12)
Any renal replacement therapy – no. (%) 0 (0)
Documented infection in CVICU – no. (%) 1 (2)
Patients in receipt of antibiotic therapy – no. (%) 4 (10)
Severity of Illness
APACHE II score 22 (4.4)
MODS postoperative day 0 6.2 (2.2)
MODS postoperative day 1 0.82 (1.5)
MODS postoperative day 2 0.63 (1.4)
MODS postoperative day 3 0.34 (1.2)
Ventilator use in days – no. (%)
1 day 36 (88)
2 days 3 (7)
3 days 1 (2)
11 days 1 (2)
Length of stay in ICU – days* 2 (2–5)
Length of hospitalization* 8 (7–10)
*Median (IQR).
OHGs: oral hypoglycemic agents; NSAID: non-steroidal anti-inflammatory drug;
ACE: angiotensin-converting-enzyme; CPB: cardiopulmonary bypass; CVICU:
cardiovascular intensive care unit; APACHE: Acute Physiology and Chronic
Health Evaluation; MODS: Multiple Organ Dysfunction Score.
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(IQR, 1–1 days) and median hospital length of stay was
8 days (IQR, 7–10 days). At the time of hospital discharge,
35 patients (85%) went home whereas the remaining pa-
tients went to a rehabilitation facility.Oral neutrophil counts and CPB-associated inflammation
A significant correlation was seen between absolute oral
neutrophil counts measured by oral swab as compared
to oral rinse (rho = 0.83 [p < 0.001] and 0.70 [p < 0.001]
for T0 and T3, respectively). No significant correlation
was seen between absolute oral neutrophil counts as
measured by oral swab and circulating neutrophils mea-
sured in the peripheral circulation at any time point
(Table 2). A significant difference was seen in the median
oral neutrophil counts (oral swab) between both T0 and T1
(1.0×106; IQR, 3.9×105 – 3.3×106; p < 0.001) and between
T0 and T2 (1.3×10
5; IQR, −1.1×105 – 5.9×105; p = 0.03) but
not between T0 and T3 (1.6×10
4; IQR, −2.8×105 – 2.3×105;
p = 0.95; Table 3). Similar results were found with the oral
rinse. Median differences in neutrophil counts in the
peripheral circulation were 8.3×109 (IQR, 4.7×109 –
1.1×1010), 6.7×109 (IQR, 4.9×109 – 1.1×1010), 4.7×109
(IQR, 3.1×109 – 7.1×109), and 1.5×109 (IQR, 8.0×108 –
3.1×109) between T1, T2, T3, T7 and T0, respectively.
Significant increases were seen in the absolute neutro-
phil counts in the blood between T0 and all other time
points, including day 7 (p < 0.001).
We first looked at univariate associations between change
in oral neutrophils immediately following CPB (T0 – T1)
and age, body mass index, gender, smoking status (only 5
patients were active smokers), use of immune mediating
medication (statins/NSAIDs/ACE inhibitors or plavix), pre-
operative chlorhexidine rinse, blood transfusion, intraopera-
tive temperature low, CPB time, cross-clamp time, number
of vessels bypassed, valve replacement, aortic graft (only 5
patients), delta creatinine and need for vasopressors. Need
for intraaortic balloon pump (IABP) or renal replace-
ment therapy and intra-operative solumedrol adminis-
tration could not be considered as no patient received
RRT, only one patient required IABP, and one patient re-
ceived intraoperative solumedrol administration. The only
variables with p-value <0.2 in the univariable analysis is
preoperative chlorhexidine wash (p-value = 0.01) and
therefore no multiple regression analysis was performed.
The same variables were used in univariable analyses
(t-test or Pearson’s correlation for continuous variables)
for change in oral neutrophils between T0 and T3. The fol-
lowing variables had a p-value <0.2: gender (p = 0.032),
use of an immune mediating medication (p = 0.14), blood
transfusion (p = 0.06), valve replacement (p = 0.017), aorta
graft (p = 0.1; only 5 patients in aorta graft), intraoperative
temperature low (p = 0.08), and greater number of vessels
bypassed (p = 0.001). We started with all variables in the
multiple regression models and then used backward selec-
tion method; in the final model gender was removed as
not significant and only number of vessels bypassed was
left (p = 0.001).
Analysis of oral neutrophil counts identified two popula-
tions differentiated by their immediate response to CBP
Table 2 Correlation between neutrophils collected from the oral cavity and peripheral blood
Oral neutrophil counts Peripheral blood neutrophil counts
Correlation (95% CI) p-value for null hypothesis rho = 0 Correlation (95% CI) p-value for null hypothesis rho = 0
Oral swab T0 0.83 (0.70, 0.91) <0.0001 −0.01 (−0.32, 0.30) 0.95
Oral swab T1 NA .. −0.04 (−0.35, 0.28) 0.81
Oral swab T2 NA .. −0.01 (−0.32, 0.30) 0.94
Oral swab T3 0.70 (0.48, 0.83) <0.0001 −0.11 (−0.41,0.21) 0.49
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Figure 1). Group 1 had baseline (T0) oral neutrophil
counts ≤1×106; and oral neutrophil counts did not signifi-
cantly change after CPB (T1 ≤ 1.6×10
5; IQR, 1.1×105 –
4.8x105). Group 2 had higher baseline oral neutrophil
counts (T0 ≥ 1×10
6) that increased significantly after CPB
(T1 = 1.9×10
6; IQR, 8.7×105 – 4.0×106; p-value = 0.0002).
No statistically significant difference was seen between
median oral neutrophil counts at any other time point be-
tween these patient groups (Table 4).
Biomarkers and CPB
Serum levels of IL-1β, IL-6, IL-10, MCP-1, IL-12 and IL-
1RA significantly increased after CPB (T0 as compared to
T1): mean difference, 1.45 ng/mL, 197.6 ng/mL, 28.2 ng/
mL, 181.1 ng/mL, 9.1 ng/mL, and 4533.9 ng/mL, respect-
ively. No significance difference in IL-2, IL-17, sICAM
and GM-CSF levels were seen between T0 as compared to
T1: mean difference, −1.0 ng/mL (p = 0.56), −1.3 ng/mL
(p = 0.23), −3493.7 ng/mL (p = 0.42) and −6.56 ng/mL
(p = 0.34) (p = 0.18; Figures 2 and 3).
Neutrophil counts, biomarkers and severity of illness
markers
All patients included survived to hospital discharge. Of
special note, 3 (7%) of patients had a documented infec-
tion (clinical suspicion and positive cultures) and the
mean change creatinine was 6 μmol/L (SD, ±17 μmol/L).
No significant correlations were seen between the
change in oral or blood neutrophil counts (T0 as com-
pared to T1) and the change in differences in the levels
of any biomarker: IL-1β (rho = 0.25; p = 0.14), IL-2Table 3 Wilcoxon signed rank test of delta neutrophils
for before and after cardiopulmonary bypass
Comparison groups Median Interquartile range (IQR) p-value
Oral swab T0:T1 1.0 x 10
6 3.9 x 105 – 3.3 x 106 < 0.001
Oral swab T0:T2 1.3 x 10
5 −1.1 x 105 – 5.9 x 105 0.03
Oral swab T0:T3 1.6 x 10
4 −2.8 x 105 – 2.3 x 105 0.95
Blood T0:T1 8.3 x 10
9 4.7 x 109 – 1.1 x 1010 < 0.001
Blood T0:T2 6.7 x 10
9 4.9 x 109 – 9.5 x 109 < 0.001
Blood T0:T3 4.7 x 10
9 3.1 x 109 – 7.1 x 109 < 0.001
Blood T0:T7 1.5 x 10
9 8.0 x 108 – 3.1 x 109 < 0.001(rho = 0.10; p = 0.55), IL-6 (rho = 0.09; p = 0.58), IL-10
(rho = −0.07; p = 0.69), IL-12 (rho = 0.14; p = 0.39), IL-
17A (rho = −0.06; p = 0.73), MCP-1 (rho = 0.11; p = 0.53),
IL-RA (rho = 0.31; p = 0.06), sICAM1 (rho = −0.01;
p = 0.98) and GM-CSF (rho = 0.02; p = 0.93). Significant
correlations however were seen between the change in log
oral neutrophil counts (T0 as compared to T1) and the
change in log levels of the biomarkers: IL-17 (rho = −0.34;
p = 0.04), and sICAM (rho = 0.32; p = 0.05). The change
seen in log blood neutrophils, comparing the same time
points was found to negatively correlate with sICAM
(rho = −0.41; p = 0.01).
Statistically significant positive correlations were seen in
the differences in log oral neutrophil counts, T0 as com-
pared to T1, and the MODS on days 1 (rho = 0.31;
p = 0.05) and 3 (rho = 0.38; p = 0.01); no significant correl-
ation was seen with MODS on day 0 or 2 (Table 5). Differ-
ences in log blood neutrophil counts, T0 as compared to
T1, were negatively correlated with MODS on days 1 and
2 (rho = −0.44 and −0.32, respectively; p < 0.01 and 0.04).
No significant correlation was seen with MODS on days 0
and 3; trends towards negative correlations (rho = −0.24
and −0.21, respectively). No significant correlation was
seen between either differences in log oral or blood neutro-
phil counts, T0 as compared to T1, and change in creatin-
ine levels (rho = 0.07; p = 0.69 and rho = −0.11; p = 0.48,
respectively).
Discussion
Temporal difference between the mean blood and oral
neutrophil counts in patients after CPB (a model of im-
mune system activation) may predict vulnerability to CPB-
related morbidity due to immune system dysregulation.
The kinetics of delivery of neutrophils to tissues may be a
more relevant determinant and marker of susceptibility to
infection, and/or ongoing inflammation, than circulating
white blood cell counts [11]. In this study, oral and blood
neutrophil counts increased immediately after CPB, how-
ever oral neutrophil counts return to baseline by day 3
whereas peripheral circulating neutrophil counts remained
(persistently) elevated at day 7. Associations between oral
neutrophils and measured biomarkers IL-17 and sICAM
before and immediately after CPB were found to be statisti-
cally significant. Interestingly, these were not the mediators
that were most changed immediately after CPB but may
Figure 1 Cardiopulmonary bypass increases both oral neutrophils (ON) [upper graph] and blood neutrophils (BN) [lower graph] counts
at T1. At T3 compared to T0, the median oral neutrophil count was similar (p = 0.95), whereas median blood neutrophil count was significantly
higher (p < 0.001).
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status [2,3,21].
Neutrophil activation is an integral component of the
systemic host response. Neutrophils are the most abundant
inflammatory cells, and their activation is essential for host
defence against bacterial or fungal infection, as well as be-
ing principally involved in host injury in states of persistent
inflammation. Neutrophil tissue repopulation followingTable 4 Wilcoxon rank-sum test of delta neutrophils for befo
tients (based on baseline oral neutrophil count)
Comparison groups Median (IQR)
Oral neutrophil counts T0 ≤ 1x10
6 /μL
Oral swab T0:T1 1.6x10
5 (1.1x105 – 4.8x105)
Oral swab T0:T2 5.4x10
4 (1.3x104 – 2.7x105)
Oral swab T0:T3 3.6x10
4 (−3.9x104 – 1.7x105)hematopoietic stem cell transplantation (HSCT) confers
protection from infection [13]; whereas an excessive PMN
response has previously been implicated in the pathogen-
esis of capillary leak syndromes resulting in decreased per-
fusion and end-organ damage, including acute respiratory
distress syndrome and MOF [22-24]. The association of in-
creased sICAM and IL-17 activity with an increase in the
number of oral neutrophils suggests that oral neutrophilre and after cardiopulmonary bypass in two groups of pa-
p-value
Oral neutrophil counts T0 ≥ 1x10
6 /μL
1.9x106 (8.7x105 – 4.0x106) 0.0002
2.7x105 (−1.3x105 – 7.0x105) 0.40
−4.4x104 (−3.8x105 – 3.7x105) 0.90
Figure 2 Cardiopulmonary bypass was associated with statistically significant increases in oral neutrophils and blood neutrophil
counts, as well as certain biomarkers (*p < 0.05; T0 vs. T1).
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acute pro-inflammatory immune response. IL-17, pro-
duced primarily by CD4+ Th17 cells, acts to enhance che-
mokine production by target cells in various tissues to
promote/attract monocytes and neutrophils to those tissue
(especially mucosal) sites, and in combination with sICAM
suggests the predominance of a Th1 phenotypic response
(acute pro-inflammatory state) [25-30]. IL-17 promotes
endothelial activation by inducing the expression of
endothelial adhesion markers (E-selectin, VCAM-1, and
ICAM-1) in a p38 MAPK-dependent manner. This
increased expression of adhesion molecules stimulates
the trans-endothelial migration of neutrophils) [25-29].
Preventing neutrophil recruitment through blocking
the action of IL-17 on endothelial cells (or on PMNs
themselves) may prove to be highly beneficial in diseases
in which neutrophilic inflammation plays a key role
[25-30]. In animal models, reducing neutrophil invasion
through IL-17A-blocking antibody has been shown to
decreased infarct size and improved neurologic out-
come in ischemic stroke [31] and has been shown to
improve survival in endotoxic shock [32,33].
The timing of neutrophil recovery to the oral cavity
following HSCT was recently found to have predictive
value for future infections post-engraftment in a paediat-
ric population [15] and be predictive of prognosis in an
adult HSCT population [34]. Further, in a murine model
the kinetics of neutrophil delivery to tissues during the
engraftment phase was a better predictor of reconstitu-
tion of the immune system than reappearance of circulat-
ing neutrophils in the blood [35]. Neutrophil delivery to
oral tissues has also been shown to predict success ofHSCTat 6 months [34]. Neutrophil recovery from the oral
cavity occurred more than one week earlier than that from
the circulating blood and the time span between blood
and oral neutrophil engraftment was inversely related to
improved outcomes (i.e. longer delays between oral and
blood engraftment predicted better outcome at 6 months)
[34]. Should patients with persistent elevations in ON
counts trend towards a worse outcome then early inter-
vention (e.g. implementing a low tidal ventilation strategy)
could decrease the pro-inflammatory cytokine response
leading to end-organ failure [36,37]. It is important to note
that there appears to be two patient populations based on
the oral neutrophil levels. The first population has no
change in their oral neutrophil levels from T0 to T1 where
as a second population (the majority of the patients) did
show an increase in that interval. This suggests that this
test may have the ability to discriminate and identify
unique patient populations based on neutrophil activation
whereas the blood levels increased in all patients. One
could hypothesize that whereas all patients had an in-
crease of neutrophil levels in the circulation either
through demargination or recruitment from the bone
marrow, one subset of patients had neutrophils activated
to the point where they were recruited into the oral cavity
whereas a second smaller subset showed no such activa-
tion. A larger trial may be able to determine if the oral
neutrophil clinical parameter has the sensitivity to identify
patients at risk of poor outcomes.
Limitations of this study would include the small num-
ber of patients and the fact that none of the patients
developed organ failure. The incidence of MOF from pa-
tients undergoing CPB is small (<5%) [38] and would
































































































Figure 3 Agreement between oral neutrophils and measured biomarkers: IL-17 and sICAM were statistically different from zero when
compared before and immediately after cardiopulmonary bypass.
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ON would predict an increase priming of PMNs and the
development of MOF. However the number of patientsin this study was chosen so as to have sufficient power
to delineate differences in oral neutrophil counts, per-
ipheral blood neutrophil counts and cytokine production
Table 5 Spearman correlation coefficients and delta neutrophils (oral and circulating blood) for before and after
cardiopulmonary bypass as compared with MODS on days 0 to 3
Comparison groups Spearman correlation coefficient, (p-value for null hypothesis rho = 0)
MODS MODS MODS MODS
day 0 day 1 day 2 day 3
Oral neutrophil counts T0:T1 0.17 (0.41) −0.18 (0.26) −0.08 (0.64) 0.10 (0.55)
Oral neutrophil counts T0:T2 −0.01 (0.97) 0.18 (0.27) 0.02 (0.20) 0.27 (0.09)
Oral neutrophil counts T0:T3 −0.23 (0.17) 0.09 (0.58) 0.14 (0.38) 0.06 (0.73)
Log oral neutrophil counts T0:T1 0.27 (0.09) 0.31 (0.05) 0.27 (0.09) 0.38 (0.01)
Log oral neutrophil counts T0:T2 0.13 (0.43) 0.35 (0.03) 0.28 (0.08) 0.39 (0.01)
Log oral neutrophil counts T0:T3 −0.14 (0.41) 0.11 (0.48) 0.12 (0.46) 0.10 (0.53)
Circulating blood neutrophil counts T0:T1 −0.17 (0.29) −0.24 (0.13) −0.21 (0.19) −0.07 (0.65)
Circulating blood neutrophil counts T0:T2 −0.28 (0.08) −0.14 (0.38) 0.01 (0.95) −0.03 (0.83)
Circulating blood neutrophil counts T0:T3 −0.43 (0.01) −0.20 (0.18) −0.13 (0.40) −0.14 (0.38)
Log circulating blood neutrophil counts T0:T1 −0.24 (0.13) −0.44 (0.01) −0.32 (0.04) −0.22 (0.17)
Log circulating blood neutrophil counts T0:T2 −0.22 (0.17) −0.25 (0.12) −0.06 (0.69) −0.14 (0.38)
Log circulating blood neutrophil counts T0:T3 −0.39 (0.01) −0.25 (0.11) −0.15 (0.35) −0.12 (0.46)
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study no patients developed organ failure, the data sug-
gests that these patients’ PMNs levels increased early fol-
lowing CPB, and therefore according to the two-hit
model of MOF [10,39], were rendered vulnerable to
end-organ dysfunction from such insults as post-
operative bleeding or infection. Further, CPB was associ-
ated with an early, transient increase in oral neutrophil
counts that correlated with the systemic inflammatory
response as measured by certain cytokines and may be
an additional marker of neutrophil or endothelial activa-
tion; identifying measures of oral neutrophil counts as a
possible earlier indicator of a patient’s vulnerability to
MOF. In addition, valuable information would be gath-
ered by assessing neutrophil function, not just absolute
number, through the measurement of myeloperoxidase
activity. The local tissue inflammatory response could be
assessed by measurement of local mediators. Given that
this was a proof of concept study these investigations
were not done. Strengths of this study would include
demonstration of feasibility, that the oral rinse and swab
provided similar results and therefore both techniques
can be performed making these methods usable in critic-
ally ill patient population. Further, while the number of
circulating PMNs seems to respond with relatively tran-
sient changes in immune status and seem to recover
more slowly, it does not provide a functional assessment
of PMN activity. Oral PMN counts are an established
measure of functional activity; oral neutrophil counts
measure PMN functional status as they reflect the ability
of PMNs to transmigrate from the circulation to the mu-
cosal surface [40-43]. Future studies will better investi-
gate the relationship between morbidity and mortality ina critically ill patient population, with the goal of identi-
fying patients at increased risk of poor outcomes.
Conclusions
 sICAM and IL-17 activity is associated with
increases in oral neutrophil number suggesting that
oral neutrophil transmigration may be a surrogate
marker of the acute pro-inflammatory immune
response.
 Future studies should investigate the relationship
between morbidity and mortality in a critically ill
patient population and oral neutrophil
transmigration, to identify patients at greatest risk of
poor outcomes.
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